BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review.
By Xin An, A. Tiwari, Yibo Sun, P. Ding, C. Ashby, Zhesheng Chen. 2010
312 citations recorded by the source corpus.
Subfields: Genetics, Hematology, Rheumatology
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- C. Scholl
- Pauline Burkhardt
- B. Brors
- B. Hutter
- A. Stenzinger
- M. Fröhlich
- O. Neumann
- Julia Ellermann
Citations in the corpus
- Accurate and efficient detection of gene fusions from RNA sequencing data (2021, background): “The most prominent examples are fusions between BCR and ABL1 in chronic myeloid leukemia and acute lymphoblastic leukemia, which can be treated effectively using imatinib and related drugs (An et al. 2010).”